ASH 2015 | Alisertib for the treatment of peripheral T-cell lymphoma
Owen A O’Connor, MD, PhD from the Columbia University Medical Center Center for Lymphoid Malignancies, New York, NY, presents the results of the first multicenter, randomized Phase III study (NCT01482962) in patients with relapsed/refractory (R/R) peripheral T-cell lymphoma (PTCL), which evaluated alisertib vs the investigator’s choice (pralatrexate, romidepsin or gemcitabine). Alisertib is a selective inhibitor of Aurora A kinase but it was not found to be superior to the comparator arm in terms of progression-free survival (PFS). He explains some of the key findings and also talks about data from another study showing a synergy between alisertib and romidepsin.
The results were presented at the American Society of Hematology (ASH) 2015 Annual Meeting in Orlando, FL.
Get great new content delivered to your inboxSign up